https://www.lezdotechmed.com/blog/product-liability/taxotere-lawsuits-update/
In the recent past United States has seen many mass tort litigations on Morcellator, AFFF, Invokana, Tylenol, Beovu and so on. One among them if the Taxotere lawsuits.
Breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head and neck cancer are only a few of the malignancies that are treated using the chemotherapy medication taxotere. It belongs to the taxane class of medications and goes by the generic name of docetaxel. A black box warning on the medication's label lists five potentially deadly side effects, including decreased blood cell count (neutropenia), liver toxicity, fluid retention, hypersensitivity reactions, and toxic death.
The breast cancer chemotherapy medicine Taxotere is made by the international pharmaceutical corporation Sanofi, which has its headquarters in France. Rhone-Poulenc invented it first (now Sanofi-Aventis). In 1996, the FDA approved taxotere for the treatment of individuals with locally advanced or metastatic breast cancer who had not responded favourably to previous therapies.
21,037 adverse events with Taxotere medications were reported to the FDA Adverse Event Reporting System between 2003 and June 2018. (FAERS). 3,007 of those reports—17,346 of them intense—led to fatalities.
According to the study, up to 6.3 percent of breast cancer patients had persistent, substantial alopecia (PSA), meaning that less than half of their hair grew back following therapy. Losing their hair had a long-lasting, negative physical and emotional impact on many women, even though it was not a life-threatening situation. The hair will never grow back because Taxotere renders the loss irreversible, even years after the completion of the chemotherapy treatment.
According to a 2001 Journal of Ophthalmology paper, Taxotere infusions caused epiphora in cancer patients. Up to 64% of Taxotere patients were discovered to be susceptible to developing epiphora, according to a study from 2014 published by the National Center for Biotechnology Information (NCBI).
In Louisiana, an MDL 2740 including about 33 lawsuits was established in October 2016 and is presided over by Judge Jane Triche Milazzo. The first trial ended in the manufacturer's favour because the judge did not believe that the medicine was to blame for Barbara Earnest's irreversible hair loss. Sanofi suffered a severe setback in early February 2022 when the appeal of the first bellwether plaintiff Barbara was taken into account and the ruling was upheld by the 5th U.S. Circuit Court of Appeals Judge Cory Wilson.
With Elizabeth Kahn as the plaintiff in the Taxotere lawsuit 2021, Sanofi won a second bellwether trial lawsuit in a row. Many plaintiffs who suffered eye injuries began suing Sanofi-Aventis across the U.S. when the Taxotere hair loss claims were being tried on one side. In a separate MDL 3023, presided over by Judge Jane Triche Milazzo in the federal district court of Louisiana, more than 12,000 eye damage complaints have been merged. Pre-trial proceedings are underway in the Taxotere case 2022.
LexDo techmed does medical record reviews for most of the Mass tort and product liability litigations like Essure, Roundup, IVC filter, Elmiron, 3M and so on. Be it medical chronology, narrative summary or deposition summary, get expert reviews from LezDo techmed to fortify your claims.
